EGFR exon 20 insertions in non-small cell lung cancer (NSCLC) are clinically important but challenging biomarkers to detect rapidly and accurately. Rapid, broad testing is essential to identify these alterations and guide targeted treatment. The Oncomine Dx Express Test is a next‑generation sequencing (NGS) in vitro diagnostic (IVD) that delivers results from tissue to report in as little as 24 hours, as a companion diagnostic (CDx) for EGFR exon 20 insertions in NSCLC and tumor profiling across multiple solid tumors. The test detects a broad spectrum of alterations—including heterogeneous EGFR exon 20 insertions—and its automated workflow minimizes hands‑on time and bioinformatics burden, enabling adoption in diverse laboratory settings. Hear testing strategies, validation data, and practical implementation of rapid NGS to support timely therapy decisions.
